39.84
+1.49(+3.89%)
Currency In USD
| Previous Close | 38.35 |
| Open | 36.78 |
| Day High | 41.64 |
| Day Low | 36.37 |
| 52-Week High | 41.64 |
| 52-Week Low | 6.76 |
| Volume | 468,705 |
| Average Volume | 344,561 |
| Market Cap | 138.01M |
| PE | -5.5 |
| EPS | -7.25 |
| Moving Average 50 Days | 17.95 |
| Moving Average 200 Days | 16.14 |
| Change | 1.49 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $2,682.83 as of December 21, 2024 at a share price of $39.84. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $3,356.36 as of December 21, 2024 at a share price of $39.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics to Present at Investor Conferences in December
GlobeNewswire Inc.
Nov 26, 2024 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
GlobeNewswire Inc.
Nov 19, 2024 6:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 06, 2024 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral